Form 4: Paya Acquires Collegium Pharmaceutical Stock

Carlos V. Paya, a Director at Collegium Pharmaceutical, Inc., acquired 8,741 shares of common stock through a grant of restricted stock units.

Summary

• Carlos V. Paya, a Director of Collegium Pharmaceutical, Inc., acquired 8,741 shares of common stock on May 14, 2026.
• This acquisition was made through a grant of restricted stock units (RSUs).
• The RSUs vest on May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, contingent upon continued service.
• Settlement of the RSUs will occur on the vesting date, or earlier upon the director's election, end of service, death, disability, or change in control, in shares of common stock.
• Following this transaction, Paya beneficially owns 28,323 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction related to director compensation rather than a significant strategic or financial event.

Positives

• Director Carlos V. Paya has increased his beneficial ownership of Collegium Pharmaceutical stock.
• The acquisition of 8,741 shares through RSUs indicates a long-term incentive aligned with continued service and company performance.
• The vesting schedule and settlement conditions suggest a focus on director retention and alignment with shareholder interests.

Risks

• The vesting of RSUs is contingent upon the director's continued service, implying a risk of forfeiture if service is terminated before the vesting date.
• Potential for dilution exists if a large number of RSUs are exercised across multiple directors.
• The settlement of RSUs can be triggered by a change in control, which may not always be favorable to existing shareholders.

Future Outlook

The RSUs are set to vest on May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service. Settlement will occur on the vesting date or earlier under specific conditions such as a change in control.

Industry Context

StockSavvy.ai notes that the granting of Restricted Stock Units (RSUs) to directors is a common practice in the pharmaceutical industry to incentivize long-term commitment and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The transaction reflects a standard compensation practice for directors, aligning their interests with the company's long-term performance through equity incentives.
• Employees: Indirectly, the continued service of directors incentivized by these RSUs can contribute to stable leadership and strategic direction.
• Management: The RSU grant is a component of executive compensation, designed to retain key leadership.

Next Steps

• Vesting of RSUs on or before May 14, 2027.
• Potential settlement of RSUs upon vesting or earlier under specified conditions.

Key Dates

Keywords

Form 4, SEC Filing, Insider Transaction, Collegium Pharmaceutical, Carlos V. Paya, Restricted Stock Units, RSU Grant, Beneficial Ownership, Director Compensation